Watchlist Price Alert

Incyte Corporation (INCY)

NASDAQ: INCY · Real-Time Price · USD

62.11

-0.42 (-0.67%)

At close: May 05, 2025, 3:59 PM

62.11

0.00%

After-hours: May 05, 2025, 07:35 PM EDT

-0.67% (1D)

Bid	60
Market Cap	12.02B
Revenue (ttm)	4.41B
Net Income (ttm)	21.27M
EPS (ttm)	0.2
PE Ratio (ttm)	310.55
Forward PE	9.52
Analyst	Hold

Ask	64
Volume	969,563
Avg. Volume (20D)	2,102,185
Open	62.27
Previous Close	62.53
Day's Range	61.90 - 62.80
52-Week Range	52.81 - 83.95
Beta	0.90

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chr...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 4, 1993

Employees 2,617

Stock Exchange NASDAQ

Ticker Symbol INCY

Website https://www.incyte.com

Full Company Profile

Analyst Forecast

According to 19 analyst ratings, the average rating for INCY stock is "Hold." The 12-month stock price forecast is $71, which is an increase of 14.31% from the latest price.

Stock Forecasts

Earnings Surprise

Incyte has released their quartely earnings on Apr 29, 2025:

Revenue of $1.05B exceeds estimates by $57.57M, with 19.54% YoY growth.

EPS of 1.16 exceeds estimates by 0.13, with 81.25% YoY growth.

Why Price Moved

6 days ago

+1.53%

INCY stock has given up its prior gain. Incyte sha... Unlock content with Pro Subscription

1 week ago

+1.53%

Incyte shares are trading higher after the company reported better-than-expected Q1 financial results

News

1 week ago · seekingalpha.com

Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript

Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Office...

1 week ago · zacks.com

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

6 days ago · zacks.com

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

6 days ago · zacks.com

Incyte (INCY) Q1 Earnings and Revenues Top Estimates

Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.

6 days ago · reuters.com

Incyte raises 2025 sales forecast for blood cancer drug after solid quarter

Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.

6 days ago · businesswire.com

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs.

1 week ago · businesswire.com

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025.

1 week ago · zacks.com

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

2 weeks ago · zacks.com

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago · businesswire.com

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Load More News